Our Approach

Xilio has developed a proprietary, clinically validated platform technology for developing tumor-activated biologics. We are advancing a pipeline of novel clinical and preclinical immunotherapies designed to achieve tumor-selective activation, including masked bispecifics and masked T cell engagers. Our molecules leverage masking and other unique components that are optimized for the specific target to focus activity within the tumor microenvironment and minimize systemic toxicity, which has limited the therapeutic potential of immuno-oncology agents to date.